The European Commission has authorized the use of Leqembi, the first drug approved in the EU that slows down Alzheimer’s disease in its early stages.

Approval of Leqembi: a landmark breakthrough in Alzheimer's treatment

The European Commission (EC) has authorized the use of Leqembi (lecanemab), the first drug approved in the European Union to slow cognitive deterioration in the early stages of Alzheimer's disease. This milestone marks a turning point in the treatment of this disease, which affects millions of people in Europe.

As already announced by the EC, this drug is intended for people with mild cognitive impairment or early Alzheimer's disease, who have only one or no copies of the ApoE4 gene and who have beta-amyloid plaques in the brain. Its approval follows a positive assessment by the European Medicines Agency (EMA), which concluded that the benefits outweigh the risks under strict conditions of use.

As Dr. Mercè Boada, co-founder and medical director of Ace, highlights, “this breakthrough is the result of decades of research, international collaboration and generosity of patients and families.” Moreover, Dr. Boada adds that this occasion “compels us to continue to move forward, ensure equal access and prepare for a new era in the approach to Alzheimer's.”

For her part, Miren Jone Gurrutxaga, CEO of Ace, stresses that "investing in science is investing in healthy societies. This breakthrough brings hope and a clearer roadmap for the clinical management of this disease."

According to the note published by the European Commission, further information will soon be available in the Union Register of Medicinal Products.

At Ace, we will continue to work to lead this new stage in the treatment of Alzheimer's disease, offering our expertise and collaboration in the diagnosis and research of this disease.

Ace:
News